Precigen, Inc., a leader in gene and cellular therapies, is revolutionizing the biopharmaceutical industry with their innovative technology. The company operates through two dynamic segments, Biopharmaceuticals and Exemplar, and provides cutting-edge disease-modifying therapeutics, genetically engineered swine, and reproductive technologies. In addition, Precigen offers a diverse portfolio of advanced genetic components, including the UltraVector platform and mbIL15 gene, designed to enhance immune cell function. Precigen also specializes in non-viral transposon/transposase systems, breaking and rejoining DNA at specific sequences, and engineered adenovectors for gene delivery. With collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC, Precigen is poised to make a significant impact on the future of medicine. Headquartered in Germantown, Maryland, Precigen, Inc. was founded in 1998 and was known as Intrexon Corporation before changing its name in January 2020.
Precigen's ticker is PGEN
The company's shares trade on the NASDAQ stock exchange
They are based in Germantown, Maryland
There are 201-500 employees working at Precigen
It is precigen.com/about
Precigen is in the Healthcare sector
Precigen is in the Biotechnology industry
The following five companies are Precigen's industry peers: